Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
sell

Alnylam Pharmace. sell nvestor

Alnylam Pharmace.
Start price
€238.30
31.08.24 / 50%
Target price
€120.00
31.08.25
Performance (%)
0.80%
End price
€240.20
14.09.24
Summary
This prediction ended on 14.09.24 with a price of €240.20. The SELL prediction by nvestor for Alnylam Pharmace. closed nearly unchanged from the start price. nvestor has 50% into this prediction

Alnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.

Performance without dividends (%)
Name 1w 1m 1y
Alnylam Pharmace. -1.917% -1.917% 20.130%
iShares Core DAX® -6.016% -4.595% 1.274%
iShares Nasdaq 100 0.511% 0.164% 14.573%
iShares Nikkei 225® -7.156% -2.215% 28.107%
iShares S&P 500 -0.257% -0.841% 10.196%

Comments by nvestor for this prediction

In the thread Alnylam Pharmace. diskutieren
Prediction Sell
Perf. (%) 0.80%
Target price 120.000
Change
Ends at

Sell mit Kursziel 120,0

nvestor 
0
Report Share
31.08.24
In the thread Trading Alnylam Pharmace.
Prediction Sell
Perf. (%) 0.80%
Target price 120.000
Change
Ends at 31.08.25

Einschätzung wurde nach dem Ende von Catch the Monkey automatisch beendet.

nvestor 
0
Report Share
14.09.24